Hyperbaric oxygen therapy for chronic systemic infections in chronic fatigue syndrome

Objective: The aim of this study was to determine if hyperbaric oxygen treatment (HBOT) could be used as adjunctive therapy and if HBOT could increase the quality of life in such a way that the functional status would improve in patients with an infection. Methods: Randomized, controlled trial: Fifteen infected CFS (CDC 1994) patients and 14 CFS (CDC 1994) patients with no evidence of a mycoplasma infection were enrolled in a convenience randomisation sample from our referral clinic. Results: No Statistical differences were found by use of univariate repeated measures although Bodily Pain as measured by the SF-36 seems to decrease after hyperbaric therapy (Greenhouse-Geisser: p = .010). Trends were found using paired t-testing for mycoplasma infected CFS patients. The general perceived fatigue seemed to decrease after hyperbaric therapy (General Fatigue: p = .06). Directly after one week of hyperbaric therapy general fatigue improved (p = .03) but there was a reduction of activity (reduced activity: p= .05) and general perceived health (general health: p = .04). One month later the physical role increased (Role-Physical: p = .07). Conclusions: Although more data is required to make firm conclusions, trends were found. Reduced fatigue, increased levels of activity and an improved reaction time improved significantly their quality of life and therfore, enhanced also their functional status and thus could be used as an adjunctive therapy.